InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
0.00%
)
US TECH 100
19,185.20
(
0.09%
)
Dow Jones
38,589.16
(
0.00%
)
Brent Oil
82.60
(
0.58%
)
Bitcoin
65,503.83
(
-1.70%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 162

Monday, 05/14/2018 5:45:10 PM

Monday, May 14, 2018 5:45:10 PM

Post# of 438
IFRX is a recent IPO that has showed significant institutional support.

Lead program is enrolling Ph2B to study first-in-class anti-human complement factor antibody in patients with Hidranitis Suppurativa (HS).

The data for this study will be available H-1/2019.

Presently, 50% of HS patients do not respond to the only approved treatment.

5/3/18, IFRX raised $51mn in a secondary stock offering.

CCXI is in Ph3 with a treatment targeting the same receptor. Interestingly, CCXI MC is only 66% of IFRX MC.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up